News
Morgan Stanley Maintains Overweight on Pharvaris, Maintains $34 Price Target
22 Apr 24
News, Price Target, Analyst Ratings
Morgan Stanley Maintains Overweight on Pharvaris, Lowers Price Target to $34
15 Apr 24
News, Price Target, Analyst Ratings
JMP Securities Maintains Market Outperform on Pharvaris, Raises Price Target to $50
11 Apr 24
News, Price Target, Analyst Ratings
Wedbush Reiterates Outperform on Pharvaris, Maintains $35 Price Target
11 Apr 24
News, Price Target, Reiteration, Analyst Ratings
Pharvaris Q4 EPS $(0.80) Misses $(0.58) Estimate
10 Apr 24
Earnings, Earnings Misses, News
Pharvaris N.V. Q4 2023 EPS €(0.74) Vs €(1.16) YoY; Cash And Cash Equivalents Were ~€391 Million As Of December 31, 2023
10 Apr 24
Earnings, News
JMP Securities Reiterates Market Outperform on Pharvaris, Maintains $49 Price Target
14 Feb 24
News, Price Target, Reiteration, Analyst Ratings
Press releases
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
10 Apr 24
Earnings, News, Health Care, Press Releases
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
10 Apr 24
Health Care, Press Releases, General
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
4 Apr 24
News, Press Releases
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
6 Mar 24
News, Press Releases
Pharvaris to Participate in the Leerink Global Biopharma Conference 2024
5 Mar 24
News, Press Releases
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting
22 Feb 24
News, Press Releases
Pharvaris Announces Extraordinary Meeting of Shareholders
16 Feb 24
Press Releases